1. Ung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-49. doi.10.3322/caac.21660 PMid:33538338

2. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43):4846-61. doi.10.3748/wjg.v24.i43.4846 PMid:30487695 PMCid:PMC6250924

3. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018; 267(5): 936-45. doi.10.1097/SLA.0000000000002234 PMid:28338509

4. Çaldıran AN, Delavari S, Esmaeili M, Salami F, Rasouli SE, Fekrvand S, et al. Evaluation of the anti-cancer efficacy of cyclooxygenase inhibition in combination with nutrient starvation on pancreatic ductal adenocarcinoma in vitro. Turk J Immunol. 2024; 12(2): 53-63. doi.10.4274/tji.galenos.2025.29290

5. Liu Y, Yang C, Zhang J, Ihsan A, Ares I, Martínez M, et al. Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxidative stress, and prevention with natural plant extracts. Expert Opin Drug Metab Toxicol. 2024; 20(8):765-85. doi.10.1080/17425255.2024.2378885 PMid:38980754

6. Wang P, Chen B, Huang Y, Li J, Cao D, Chen Z, et al. The relationship between nonsteroidal anti-inflammatory drugs and cancer incidence: An umbrella review. Heliyon. 2024; 10(2): e23203. doi.10.1016/j.heliyon.2023.e23203 PMid:38312641 PMCid:PMC10834481

7. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2003; 95(23):1784-91. doi.10.1093/jnci/djg106 PMid:14652240

8. Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018; 8(7): e021869. doi.10.1136/bmjopen-2018-021869 PMid:29982219 PMCid:PMC6042574

9. Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, et al. Aspirin use and reduced risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2017; 26(1): 68-74. doi.10.1158/1055-9965.EPI-16-0508 PMid:27999143 PMCid:PMC5225096

10. Tan JT, Mao X, Cheng HM, Seto WK, Leung WK, Cheung KS. Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus. Gut. 2025; 74(4): 603-12. doi.10.1136/gutjnl-2024-333329 PMid:39746785

11. Sun J, Li Y, Liu L, Jiang Z, Liu G. Aspirin use and pancreatic cancer risk: A systematic review of observational studies. Medicine (Baltimore). 2019; 98(51): e18033. doi.10.1097/MD.0000000000018033 PMid:31860953 PMCid:PMC6940047

12. Lae Lae Phoo N, Sukhamwang A, Dejkriengkraikul P, Yodkeeree S. Diclofenac sensitizes signet ring cell gastric carcinoma cells to cisplatin by activating autophagy and inhibition of survival signal pathways. Int J Mol Sci. 2022; 23(20): 12066. doi.10.3390/ijms232012066 PMid:36292923 PMCid:PMC9602524

13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. doi.10.1016/0016-5085(94)90246-1 PMid:7926468

14. Ghanghas P, Jain S, Rana C, Sanyal SN. Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer. Biomed Pharmacother. 2016;78:239-47. doi.10.1016/j.biopha.2016.01.024 PMid:26898448

15. Yilmaz Ç, Köksoy S, Çeker T, Aslan M. Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(11): 2259-72. doi.10.1007/s00210-021-02139-6 PMid:34436652

16. Çaldıran AN, Gürel G, Aru B. Evaluation of the Anti-Cancer Efficacy of Cyclooxygenase Inhibition in Combination with Nutrient Starvation on Pancreatic Ductal Adenocarcinoma In Vitro. Turk J Immunol. 2024; 12(3):114-24. doi.10.4274/tji.galenos.2025.29290

17. Choi S, Kim S, Park J, Lee SE, Kim C, Kang D. Diclofenac: A nonsteroidal anti-inflammatory drug inducing cancer cell death by inhibiting microtubule polymerization and autophagy flux. Antioxidants (Basel). 2022; 11(5):1009. doi.10.3390/antiox11051009 PMid:35624874 PMCid:PMC9138099

18. Amanullah A, Upadhyay A, Dhiman R, Singh S, Kumar A, Ahirwar DK, et al. Development and challenges of diclofenac-based novel therapeutics: targeting cancer and complex diseases. Cancers (Basel). 2022; 14(18):4385. doi.10.3390/cancers14184385 PMid:36139546 PMCid:PMC9496891

19. Selg C, Gordić V, Krajnović T, Buzharevski A, Laube M, Kazimir A, et al. Re-design and evaluation of diclofenac-based carborane-substituted prodrugs and their anti-cancer potential. Sci Rep. 2024; 14(1):30488. doi.10.1038/s41598-024-81414-x PMid:39681576 PMCid:PMC11649784

20. Dronik M, Stasevych M. Expanding Horizons: Opportunities for Diclofenac Beyond Traditional Use-A Review. Sci Pharm. 2025; 93(3):31. doi.10.3390/scipharm93030031

21. Esmaeilzadeh A, Bagheri Hosseini H, Mehdi Pakdaman S, Jamali J. Effect of diclofenac suppository in bleeding and pancreatitis incidence rate after ERCP in patients with common bile duct stones. Med J Mashhad Univ Med Sci. 2015; 58(9):505-15.

22. Mayorek N, Naftali-Shani N, Grunewald M. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS One. 2010; 5(9):e12715. doi.10.1371/journal.pone.0012715 PMid:20856806 PMCid:PMC2939880

23. Jaros SW, Komarnicka UK, Kyzioł A, Pucelik B, Nesterov DS, Kirillov AM, et al. Therapeutic potential of a water-soluble silver-diclofenac coordination polymer on 3D pancreatic cancer spheroids. J Med Chem. 2022; 65(16):11100-10. doi.10.1021/acs.jmedchem.2c00535 PMid:35969454 PMCid:PMC9776540

24. Tahazadeh H, Pazhang Y. Synergistic Effect of Dexamethasone and Diclofenac on Viability of K562 Cells. J Gorgan Univ Med Sci. 2022; 24(2):53-62.

25. Liu W, Yu X, Yuan Y, Feng Y, Wu C, Huang C, et al. CD73, a promising therapeutic target of diclofenac, promotes metastasis of pancreatic cancer through a nucleotidase independent mechanism. Adv Sci (Weinh). 2023; 10(6):2206335. doi.10.1002/advs.202206335 PMid:36563135 PMCid:PMC9951332

26. Bombardo M, Malagola E, Chen R, Rudnicka A, Graf R, Sonda S. Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. Br J Pharmacol. 2018; 175(2):335-47. doi.10.1111/bph.13867 PMid:28542719 PMCid:PMC5758389

27. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 2000; 51(1):511-23. doi.10.1146/annurev.med.51.1.511 PMid:10774479